Palvella Therapeutics, Inc. (PVLA) Income from Continuing Operations (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Income from Continuing Operations for 12 consecutive years, with 3951000.0 as the latest value for Q4 2024.
- On a quarterly basis, Income from Continuing Operations fell 128.55% to 3951000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 17434000.0, a 74.03% decrease, with the full-year FY2024 number at 17434000.0, down 193.27% from a year prior.
- Income from Continuing Operations was 3951000.0 for Q4 2024 at Palvella Therapeutics, up from 6775000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 13841000.0 in Q4 2023 to a low of 19008000.0 in Q3 2021.
- A 5-year average of 7772100.0 and a median of 9232500.0 in 2021 define the central range for Income from Continuing Operations.
- Peak YoY movement for Income from Continuing Operations: tumbled 1508.69% in 2020, then surged 223.93% in 2023.
- Palvella Therapeutics' Income from Continuing Operations stood at 12403000.0 in 2020, then increased by 11.27% to 11005000.0 in 2021, then dropped by 1.48% to 11168000.0 in 2022, then soared by 223.93% to 13841000.0 in 2023, then tumbled by 128.55% to 3951000.0 in 2024.
- Per Business Quant, the three most recent readings for PVLA's Income from Continuing Operations are 3951000.0 (Q4 2024), 6775000.0 (Q3 2024), and 4172000.0 (Q2 2024).